Translated by TIAN Ran 1,2 , LAM Wai Ching 1,2 , DUAN Yuting 1,2 , BIAN Zhaoxiang 1,2 , ZHANG Chi 3 , SHANG Hongcai 3 , 譯
  • 1. School of Chinese Medicine, Hong Kong Baptist University, HongKong 999077, P.R.China;
  • 2. Chinese EQUATOR Centre, HongKong 999077, P.R.China;
  • 3. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P.R.China;
BIAN Zhaoxiang, Email: bianzxiang@gmail.com
10.7507/1672-2531.202008178
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

草藥產品被廣泛使用，其成分及質量差異很大，在隨機對照試驗（randomized controlled trials，RCTs）中也十分常見。筆者基于 22 項 CONSORT 條目清單，對含草藥干預措施 RCTs 的報告內容提出推薦條目。經過電話溝通，筆者于加拿大多倫多與 16 位專家進行了專家共識會議。工作組通過了 9 項草藥 RCTs 的 CONSORT 清單條目，其中針對草藥干預措施的條目 4 闡述最為詳盡。這些推薦將會用于改善草藥干預措施 RCTs 的報告。

Citation： Translated by TIAN Ran, LAM Wai Ching, DUAN Yuting, BIAN Zhaoxiang, ZHANG Chi, SHANG Hongcai. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Chinese Journal of Evidence-Based Medicine, 2021, 21(1): 97-99. doi: 10.7507/1672-2531.202008178 Copy

Copyright ? the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved

  • Previous Article

    Rational use of oral H1 receptor antagonists in children: a clinical practice guideline protocol